Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice

Chronic kidney disease mineral bone disorders (CKD-MBD) encompass laboratory, vascular and bone abnormalities that might portend a poor prognosis in CKD. In spite of a great effort in elucidating the CKD-MBD natural history and pathogenesis, the underlying mechanisms are still largely unknown. However, a deficit in vitamin D is commonly reported as one of the first steps in CKD-MBD, and numerous epidemiological studies have associated serum vitamin D levels with different markers of cardiovascular disease and the risk of death in different populations. We herein summarize current evidence that links vitamin D deficiency to an adverse outcome and the results of the most recent clinical trials that have investigated the impact of paricalcitol supplementation on hard outcome in CKD patients.

[1]  L. Ghiadoni,et al.  Cholecalciferol administration blunts the systemic renin–angiotensin system in essential hypertensives with hypovitaminosis D , 2014, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[2]  J. Floege,et al.  Medical options to fight mortality in end-stage renal disease: a review of the literature. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  M. Wolf,et al.  Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  S. Solomon,et al.  Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. , 2012, JAMA.

[5]  E. Schiffrin,et al.  T Regulatory Lymphocytes Prevent Aldosterone-Induced Vascular Injury , 2012, Hypertension.

[6]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[7]  M. Tokumoto,et al.  Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. , 2011, Kidney International.

[8]  E. Schiffrin,et al.  T Regulatory Lymphocytes Prevent Angiotensin II–Induced Hypertension and Vascular Injury , 2011, Hypertension.

[9]  H. Parving,et al.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial , 2010, The Lancet.

[10]  M. Wolf,et al.  Forging forward with 10 burning questions on FGF23 in kidney disease. , 2010, Journal of the American Society of Nephrology : JASN.

[11]  W. März,et al.  Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients , 2010, European heart journal.

[12]  M. Tokumoto,et al.  Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  S. Mihaila.  Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. , 2010, Maedica.

[14]  K. Schechtman,et al.  1,25(OH)2 Vitamin D Inhibits Foam Cell Formation and Suppresses Macrophage Cholesterol Uptake in Patients With Type 2 Diabetes Mellitus , 2009, Circulation.

[15]  Zhongyi Zhang,et al.  Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. , 2008, Kidney international.

[16]  S. Fishbane,et al.  Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[17]  G. Curhan,et al.  Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension Among Young Women , 2008, Hypertension.

[18]  G. Ning,et al.  Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase , 2008, Proceedings of the National Academy of Sciences.

[19]  W. März,et al.  Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. , 2008, The Journal of clinical endocrinology and metabolism.

[20]  Youhua Liu,et al.  Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. , 2008, Journal of the American Society of Nephrology : JASN.

[21]  N. Wareham,et al.  Baseline Serum 25-Hydroxy Vitamin D Is Predictive of Future Glycemic Status and Insulin Resistance , 2008, Diabetes.

[22]  T. Cole,et al.  A bimodal association of vitamin D levels and vascular disease in children on dialysis. , 2008, Journal of the American Society of Nephrology : JASN.

[23]  C. Mathieu,et al.  Vitamin D and human health: lessons from vitamin D receptor null mice. , 2008, Endocrine reviews.

[24]  T. Akizawa,et al.  Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. , 2007, Journal of the American Society of Nephrology : JASN.

[25]  Edward Giovannucci,et al.  Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension , 2007, Hypertension.

[26]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[27]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[28]  V. Vaccarino,et al.  Vitamin D status and coronary flow reserve measured by positron emission tomography: a co-twin control study. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  Youhua Liu,et al.  Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. , 2011, Journal of the American Society of Nephrology : JASN.

[30]  C. Zoccali,et al.  Vitamin D levels and patient outcome in chronic kidney disease. , 2009, Kidney international.

[31]  Olivier Moranne,et al.  Timing of onset of CKD-related metabolic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[32]  F. Locatelli,et al.  The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. , 2008, Clinical journal of the American Society of Nephrology : CJASN.